Kidney Cancer

Clinical Trials

Below is a list of Kidney Cancer clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

Phase 3 Study of Treatment for Newly Diagnosed Higher Risk Favorable Histology Wilms Tumor
Patients are being asked to take part in this study because they have a Wilms tumor in which the cancer cells look almost like normal cells in the kidney (this is called favorable histology).
There is, however, some risk that the cancer will return after treatment.

It is common to enroll children and adolescents with cancer in a clinical trial that seeks to
improve cancer treatment over time. Clinical trials include only people who choose to take
part. Patients have a choice between a standard treatment for Wilms tumor and this clinical trial.
The usual treatment for people with these tumors is to have surgery to remove as much tumor as possible, then anti-cancer drug therapy (chemotherapy), and some therapy with high energy X-ray (radiation therapy).

Chemotherapy and radiation have side effects and late effects, so study doctors are trying to find out the amount of treatment to give patients that will treat their cancer and at the same time have less of these effects. Late effects are health problems that happen to patients later in life because of the drugs or radiation used to treat their cancer. Late effects may include health problems such as poor growth, inability to have children, impaired organ function (such as problems with breathing, poor heart function or heart failure) or the development of a second type of cancer.

The overall goal of this study is to find out if:
Patients with Wilms tumor that has spread only to their lungs can be treated without having radiation therapy to their lungs. Patients whose lung tumors go away completely after the first six weeks of standard chemotherapy will not have to have radiation therapy

Patients with Wilms tumor that has spread only to their lungs whose lung tumors do not go away after the first six weeks of standard chemotherapy for Wilms tumor can be treated by using two additional chemotherapy drugs, plus radiation therapy

Patients who have Wilms tumor that has spread to other parts of the body in addition to or instead of in the lungs, can be treated by using two additional chemotherapy drugs along with the standard drugs, and radiation therapy

Some genetic information about the tumor cells can help the researchers put patients in the experimental treatment group.
Read more

Phase 3 Study to Evaluate Adjuvant cG250 Treatment vs. Placebo in Patients with Clear Cell Renal Cell Cancer and at High Risk for Recurrence
This study is being done to learn the effectiveness and safety of the investigational drug, cG250, to prevent or delay tumor recurrence when compared to a placebo (an inactive substance that looks the same as the study drug).

The study drug, cG250 is considered investigational because it is not approved by the U.S. Food and Drug Administration (FDA) for routine clinical use. The FDA has, however, approved the use of cG250 for this research study. cG250 has the potential to recognize and bind to cancer cells of the kidney. With this binding, the cancer cells are marked for destruction by a patient's immune system and a mechanism to destroy the cells can be activated.
Read more

12345 A Study to Evaluate Changes in Phosphate Regulating Factors in Patients with Advanced Renal Cell Carcinoma (RCC) Treated with Sorafenib (Nexavar)
Patients are being asked to take part in this research study because they have a disease called advanced renal cell carcinoma (RCC). Patients will be taking a drug called sorafenib (Nexavar). Sorafenib is an anti-cancer medication that is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of renal cell carcinoma.
The results of this study may help researchers understand how treating RCC patients with sorafenib may be linked to low phosphorous level in the blood, and how this low phosphorous level may or may not affect bone mineral density (BMD). Bone mineral density is a way of measuring bone strength. By measuring BMD it is possible to predict bone fracture risk in the same manner that measuring blood pressure can help predict the risk of stroke. The research staff also want to learn whether sorafenib treatment has any effect on the ability of the heart to pump blood efficiently.
Read more

A Study to Evaluate Changes in Phosphate Regulating Factors in Patients with Advanced Renal Cell Carcinoma (RCC) Treated with Sorafenib (Nexavar)
Patients are being asked to take part in this research study because they have a disease called advanced renal cell carcinoma (RCC). Patients will be taking a drug called sorafenib (Nexavar). Sorafenib is an anti-cancer medication that is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of renal cell carcinoma. The results of this study may help researchers understand how treating RCC patients with sorafenib may be linked to low phosphorous level in the blood, and how this low phosphorous level may or may not affect bone mineral density (BMD). Bone mineral density is a way of measuring bone strength. By measuring BMD it is possible to predict bone fracture risk in the same manner that measuring blood pressure can help predict the risk of stroke. The research staff also want to learn whether sorafenib treatment has any effect on the ability of the heart to pump blood efficiently.
Read more

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
This is a study for children and young adults with high-risk cancers that usually start in the kidney. The study was designed for patients with anaplastic Wilms tumor, malignant rhabdoid tumor, clear cell sarcoma of the kidney, and renal cell carcinoma. These tumors are called "high-risk" tumors because they are likely to spread to other areas of the body and/or come back during or after treatment. The high-risk kidney tumors are very rare; only about 50 children and young adults are diagnosed with a high-risk kidney tumor each year in North America. This study has different treatment "arms" that vary according to the stage and type of the tumor.
Read more

E2805, Phase 3 Trial of Sunitinib (Sutent) versus Sorafenib (Nexavar) versus Placebo in Patients with Resected (Surgically Removed) Renal Cell Carcinoma
The purpose of this study is to see if either Sunitinib or Sorafenib can prevent recurrence of a patient's kidney cancer and to compare the effects (both good and bad) of the Sunitinib and the Sorafenib with placebo (pills that look like the study drugs, but are not active or do not contain the drug) on the patient and their kidney cancer to see which is better.
Read more